LY4170156 — Investigational Agent
Antibody-Drug Conjugate · Phase 1 · Eli Lilly
Mechanism of Action
LY4170156 is a folate receptor alpha-directed antibody-drug conjugate that delivers a topoisomerase 1 inhibitor payload to FRalpha-expressing tumor cells, causing DNA damage and cell death.
Investigational Indications
- Platinum-resistant FRalpha-expressing ovarian cancer
- Endometrial cancer
- Cervical cancer